Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer.
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 07; 389(23):2162-2174.
View in:
PubMed
subject areas
Antibodies, Monoclonal, Humanized
Drug Resistance, Neoplasm
Female
Folate Receptor 1
Humans
Immunoconjugates
Maytansine
Ovarian Neoplasms
Platinum Compounds
authors with profiles
John Moroney